Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference


WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 2:55 pm EST.

A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary geographically precise solutions (GPS) platform to build a pipeline of novel, tumor-activated molecules, including antibodies, cytokines and other biologics, which are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment. Xilio is currently advancing multiple programs for tumor-activated I-O treatments in clinical development, as well as programs in preclinical development. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

For Investor and Media Inquiries: 

Julissa Viana
Vice President,
Head of Investor Relations and Corporate Communications
investors@xiliotx.com   

Melissa Forst
Argot Partners
Xilio@argotpartners.com